2230879
Project Grant
Overview
Grant Description
SBIR Phase I: Neural Blockade Monitor Technology for Precision Pain Management - The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is found in its ability to provide a novel tool for clinicians for perioperative, post-surgical, and chronic pain management. This technology supports enhanced patient safety, international standards for enhanced recovery after surgery, reduced addiction potential and opioid sparing, reduced loading on clinicians and healthcare resources, reduced cost of healthcare services, and advanced capability of clinicians through training.
The commercial impact exists in all facets of healthcare, including perioperative procedures, in-hospital step-down and recovery, ambulatory surgery center procedures, and chronic pain management. The potential exists to expand into other clinical markets including the military and first responders. This technology can support the national defense of the country by providing advanced care capability for wounded troops on the front lines, in recovery, and through rehabilitation. The solution also applies to use during times of national, state, and local crisis, and, as the hospital-at-home trend increases, that market can be pursued. Ultimately, the commercial impact exists in both worldwide use and in contributing to the overall projected increase in use of regional blocks in the coming decade.
This Small Business Innovation Research (SBIR) Phase I project applies technology to a medical application that has not been addressed for over 130 years. Based on clinical needs, a minimally viable device (MVP) has been developed and prototyped that objectively quantifies neural blockades. This project advances the capability of the MVP and advances information about the real-time in vivo status of a neural blockade. The goal is to assure device robustness under challenging clinical conditions, for different neural blockade types, and for physiologically diverse patient populations.
The plan to reach these goals is to apply human factors and design engineering standards to the MVP to assure that: a) the user displays are readily understood, provide the expected information in an appropriate form and format, and support the required clinical processes and procedures; b) the user controls perform the required functions, are complete, reflect the appropriate nomenclature for the clinical environment, and support the required clinical processes and procedures; and c) the monitor is reliable, well fabricated, safe for the patient and user, and completely supports the acquisition, processing, display, and recording of pertinent data. The resulting technology will be a robust patient monitoring device that assures patient safety and optimized treatment.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
The commercial impact exists in all facets of healthcare, including perioperative procedures, in-hospital step-down and recovery, ambulatory surgery center procedures, and chronic pain management. The potential exists to expand into other clinical markets including the military and first responders. This technology can support the national defense of the country by providing advanced care capability for wounded troops on the front lines, in recovery, and through rehabilitation. The solution also applies to use during times of national, state, and local crisis, and, as the hospital-at-home trend increases, that market can be pursued. Ultimately, the commercial impact exists in both worldwide use and in contributing to the overall projected increase in use of regional blocks in the coming decade.
This Small Business Innovation Research (SBIR) Phase I project applies technology to a medical application that has not been addressed for over 130 years. Based on clinical needs, a minimally viable device (MVP) has been developed and prototyped that objectively quantifies neural blockades. This project advances the capability of the MVP and advances information about the real-time in vivo status of a neural blockade. The goal is to assure device robustness under challenging clinical conditions, for different neural blockade types, and for physiologically diverse patient populations.
The plan to reach these goals is to apply human factors and design engineering standards to the MVP to assure that: a) the user displays are readily understood, provide the expected information in an appropriate form and format, and support the required clinical processes and procedures; b) the user controls perform the required functions, are complete, reflect the appropriate nomenclature for the clinical environment, and support the required clinical processes and procedures; and c) the monitor is reliable, well fabricated, safe for the patient and user, and completely supports the acquisition, processing, display, and recording of pertinent data. The resulting technology will be a robust patient monitoring device that assures patient safety and optimized treatment.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Awardee
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Highland,
Maryland
20777-9542
United States
Geographic Scope
Single Zip Code
Related Opportunity
None
Blocksynop was awarded
Project Grant 2230879
worth $274,686
from National Science Foundation in February 2023 with work to be completed primarily in Highland Maryland United States.
The grant
has a duration of 5 months and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I:Neural Blockade Monitor Technology for Precision Pain Management
Abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is found in its ability to provide a novel tool for clinicians for perioperative, post-surgical, and chronic pain management. This technology supports enhanced patient safety, international standards for enhanced recovery after surgery, reduced addiction potential and opioid sparing, reduced loading on clinicians and healthcare resources, reduced cost of healthcare services, and advanced capability of clinicians through training. The commercial impact exists in all facets of healthcare, including perioperative procedures, in-hospital step-down and recovery, ambulatory surgery center procedures, and chronic pain management. The potential exists to expand into other clinical markets including the military and first responders. This technology can support the national defense of the country by providing advanced care capability for wounded troops on the front lines, in recovery, and through rehabilitation. The solution also applies to use during times of national, state, and local crisis, and, as the hospital-at-home trend increases, that market can be pursued. Ultimately, the commercial impact exists in both worldwide use and in contributing to the overall projected increase in use of regional blocks in the coming decade._x000D_ _x000D_ This Small Business Innovation Research (SBIR) Phase I project applies technology to a medical application that has not been addressed for over 130 years.Based on clinical needs, a minimally viable device (MVP) has been developed and prototyped that objectively quantifies neural blockades. This project advances the capability of the MVP and advances information about the real-time in vivo status of a neural blockade. The goal is to assure device robustness under challenging clinical conditions, for different neural blockade types, and for physiologically diverse patient populations. The plan to reach these goals is to apply human factors and design engineering standards to the MVP to assure that: a) the user displays are readily understood, provide the expected information in an appropriate form and format, and support the required clinical processes and procedures; b) the user controls perform the required functions, are complete, reflect the appropriate nomenclature for the clinical environment, and support the required clinical processes and procedures; and c) the monitor is reliable, well fabricated, safe for the patient and user, and completely supports the acquisition, processing, display, and recording of pertinent data. The resulting technology will be a robust patient monitoring device that assures patient safety and optimized treatment._x000D_ _x000D_ This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
BM
Solicitation Number
NSF 22-551
Status
(Complete)
Last Modified 2/6/23
Period of Performance
2/1/23
Start Date
7/31/23
End Date
Funding Split
$274.7K
Federal Obligation
$0.0
Non-Federal Obligation
$274.7K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2230879
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
GXR5FCDU2AY7
Awardee CAGE
8R7F2
Performance District
Not Applicable
Budget Funding
Federal Account | Budget Subfunction | Object Class | Total | Percentage |
---|---|---|---|---|
Research and Related Activities, National Science Foundation (049-0100) | General science and basic research | Grants, subsidies, and contributions (41.0) | $274,686 | 100% |
Modified: 2/6/23